Active Ingredient History
Lucatumumab is a human monoclonal antibody against CD40 development of which was discontinued by Novartis in 2013 after it was investigated for the treatment of various types of cancer like multiple myeloma and follicular lymphoma. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Hodgkin Disease (Phase 1/Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Lymphoma, Follicular (Phase 1)
Lymphoma, Non-Hodgkin (Phase 1/Phase 2)
Multiple Myeloma (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue